NASDAQ:LUNG Pulmonx (LUNG) Stock Forecast, Price & News $12.75 +0.32 (+2.57%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$12.38▼$13.1450-Day Range$10.78▼$13.1352-Week Range$4.07▼$24.49Volume298,293 shsAverage Volume429,405 shsMarket Capitalization$481.31 millionP/E RatioN/ADividend YieldN/APrice Target$14.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Pulmonx MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside15.7% Upside$14.75 Price TargetShort InterestBearish8.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.06Based on 10 Articles This WeekInsider TradingSelling Shares$199,519 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.70) to ($1.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 starsMedical Sector817th out of 981 stocksSurgical & Medical Instruments Industry78th out of 97 stocks 2.3 Analyst's Opinion Consensus RatingPulmonx has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.75, Pulmonx has a forecasted upside of 15.7% from its current price of $12.75.Amount of Analyst CoveragePulmonx has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.04% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Pulmonx has recently decreased by 3.01%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUNG. Previous Next 2.3 News and Social Media Coverage News SentimentPulmonx has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Pulmonx this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Pulmonx to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $199,519.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions92.68% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pulmonx are expected to grow in the coming year, from ($1.70) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pulmonx (NASDAQ:LUNG) StockPulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Read More Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Email Address LUNG Stock News HeadlinesJune 5, 2023 | americanbankingnews.comInsider Selling: Pulmonx Co. (NASDAQ:LUNG) CEO Sells $74,998.84 in StockJune 4, 2023 | americanbankingnews.comDerrick Sung Sells 4,222 Shares of Pulmonx Co. (NASDAQ:LUNG) StockJune 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.June 4, 2023 | americanbankingnews.comDavid Aaron Lehman Sells 3,776 Shares of Pulmonx Co. (NASDAQ:LUNG) StockJune 4, 2023 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 18, 2023 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Sees Significant Decline in Short InterestMay 10, 2023 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 9, 2023 | americanbankingnews.comHead-To-Head Survey: DarioHealth (NASDAQ:DRIO) versus Pulmonx (NASDAQ:LUNG)June 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 4, 2023 | finanznachrichten.dePulmonx Corporation: Pulmonx Reports First Quarter 2023 Financial ResultsMay 4, 2023 | msn.comCitigroup Maintains ProLung (LUNG) Buy RecommendationMay 4, 2023 | americanbankingnews.comPulmonx (NASDAQ:LUNG) Announces Quarterly Earnings ResultsMay 4, 2023 | americanbankingnews.comPulmonx (NASDAQ:LUNG) Price Target Raised to $15.00 at Piper SandlerMay 3, 2023 | msn.comMorgan Stanley Maintains ProLung (LUNG) Equal-Weight RecommendationMay 3, 2023 | msn.comPiper Sandler Maintains ProLung (LUNG) Overweight RecommendationMay 3, 2023 | markets.businessinsider.com7 Analysts Have This to Say About PulmonxMay 2, 2023 | finance.yahoo.comPulmonx Reports First Quarter 2023 Financial ResultsMay 1, 2023 | benzinga.comA Preview Of Pulmonx's EarningsApril 25, 2023 | finance.yahoo.comPulmonx to Present at the Bank of America Securities 2023 Health Care ConferenceApril 25, 2023 | americanbankingnews.comPulmonx (LUNG) to Release Quarterly Earnings on TuesdayApril 18, 2023 | finance.yahoo.comPulmonx to Report First Quarter 2023 Financial Results on May 2, 2023April 17, 2023 | finance.yahoo.comPulmonx Corporation (NASDAQ:LUNG) Not Flying Under The RadarApril 13, 2023 | americanbankingnews.comAnalysts Set Pulmonx Co. (NASDAQ:LUNG) PT at $14.50April 9, 2023 | benzinga.comPulmonx Corp (LUNG) Stock: What Does the Chart Say Thursday?April 6, 2023 | benzinga.comPulmonx Stock (NASDAQ:LUNG), DividendsApril 3, 2023 | americanbankingnews.comCitigroup Raises Pulmonx (NASDAQ:LUNG) Price Target to $13.00April 3, 2023 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Sees Significant Growth in Short InterestSee More Headlines LUNG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUNG Company Calendar Last Earnings5/02/2023Today6/06/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LUNG CUSIPN/A CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees253Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.75 High Stock Price Forecast$20.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+15.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,920,000.00 Net Margins-102.69% Pretax Margin-101.97% Return on Equity-37.22% Return on Assets-29.12% Debt Debt-to-Equity Ratio0.26 Current Ratio10.61 Quick Ratio9.70 Sales & Book Value Annual Sales$53.66 million Price / Sales8.97 Cash FlowN/A Price / Cash FlowN/A Book Value$4.12 per share Price / Book3.09Miscellaneous Outstanding Shares37,750,000Free Float35,596,000Market Cap$481.31 million OptionableNot Optionable Beta0.32 Key ExecutivesMr. Glendon E. French (Age 61)CEO, Pres & Director Comp: $899.58kMr. David A. Lehman (Age 62)Gen. Counsel & Sec. Comp: $569.14kMr. Geoffrey Beran Rose (Age 50)Chief Commercial Officer Comp: $524.99kDr. Derrick Sung Ph.D. (Age 50)Chief Financial Officer Mr. Sri RadhakrishnanChief Technical OfficerMs. Lauren CristinaVP of Fin. & Admin. (U.S.)Ms. Marcee M. Maroney (Age 53)VP of Marketing Sarah HuberVP of Sales (U.S.)Ms. Lisa Paul (Age 59)Chief People Officer Mr. Jérôme ErathSr. VP & GM of Europe Middle-East & AfricaMore ExecutivesKey CompetitorsSight SciencesNASDAQ:SGHTAnika TherapeuticsNASDAQ:ANIKTactile Systems TechnologyNASDAQ:TCMDAngioDynamicsNASDAQ:ANGOCerusNASDAQ:CERSView All CompetitorsInsiders & InstitutionsGlendon E French IIISold 6,533 sharesTotal: $74,998.84 ($11.48/share)Derrick SungSold 4,222 sharesTotal: $48,510.78 ($11.49/share)Geoffrey Beran RoseSold 2,845 sharesTotal: $32,660.60 ($11.48/share)David Aaron LehmanSold 3,776 sharesTotal: $43,348.48 ($11.48/share)JPMorgan Chase & Co.Bought 90,404 shares on 5/18/2023Ownership: 0.393%View All Insider TransactionsView All Institutional Transactions LUNG Stock - Frequently Asked Questions Should I buy or sell Pulmonx stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUNG shares. View LUNG analyst ratings or view top-rated stocks. What is Pulmonx's stock price forecast for 2023? 7 brokers have issued 1 year target prices for Pulmonx's stock. Their LUNG share price forecasts range from $8.00 to $20.00. On average, they predict the company's stock price to reach $14.75 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price. View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts. How have LUNG shares performed in 2023? Pulmonx's stock was trading at $8.43 at the beginning of the year. Since then, LUNG stock has increased by 51.2% and is now trading at $12.75. View the best growth stocks for 2023 here. When is Pulmonx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our LUNG earnings forecast. How were Pulmonx's earnings last quarter? Pulmonx Co. (NASDAQ:LUNG) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.01. The company earned $14.50 million during the quarter, compared to analysts' expectations of $13.49 million. Pulmonx had a negative trailing twelve-month return on equity of 37.22% and a negative net margin of 102.69%. The company's revenue was up 34.3% on a year-over-year basis. During the same period last year, the company posted ($0.43) earnings per share. What ETFs hold Pulmonx's stock? ETFs with the largest weight of Pulmonx (NASDAQ:LUNG) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Health Care Equipment ETF (XHE), BlackRock Future Health ETF (BMED), Principal Healthcare Innovators ETF (BTEC), What guidance has Pulmonx issued on next quarter's earnings? Pulmonx updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63.00 million-$65.00 million, compared to the consensus revenue estimate of $64.44 million. When did Pulmonx IPO? (LUNG) raised $100 million in an initial public offering (IPO) on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. What is Pulmonx's stock symbol? Pulmonx trades on the NASDAQ under the ticker symbol "LUNG." Who are Pulmonx's major shareholders? Pulmonx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.17%), Braidwell LP (3.08%), FMR LLC (2.55%), State Street Corp (2.51%), Geode Capital Management LLC (1.85%) and Deutsche Bank AG (1.44%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, Richard Ferrari and Scientific Corp Boston. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pulmonx's stock price today? One share of LUNG stock can currently be purchased for approximately $12.75. How much money does Pulmonx make? Pulmonx (NASDAQ:LUNG) has a market capitalization of $481.31 million and generates $53.66 million in revenue each year. The company earns $-58,920,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. How many employees does Pulmonx have? The company employs 253 workers across the globe. How can I contact Pulmonx? The official website for the company is pulmonx.com. The company can be reached via phone at 1-650-364-0400 or via email at investors@pulmonx.com. This page (NASDAQ:LUNG) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.